HK1030771A1 - Tetrazole-containing rapamycin analogs with shortened half-lives - Google Patents

Tetrazole-containing rapamycin analogs with shortened half-lives

Info

Publication number
HK1030771A1
HK1030771A1 HK01100137A HK01100137A HK1030771A1 HK 1030771 A1 HK1030771 A1 HK 1030771A1 HK 01100137 A HK01100137 A HK 01100137A HK 01100137 A HK01100137 A HK 01100137A HK 1030771 A1 HK1030771 A1 HK 1030771A1
Authority
HK
Hong Kong
Prior art keywords
tetrazole
lives
rapamycin analogs
containing rapamycin
shortened half
Prior art date
Application number
HK01100137A
Other languages
English (en)
Inventor
Karl W Mollison
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1030771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1030771A1 publication Critical patent/HK1030771A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HK01100137A 1997-09-26 2001-01-05 Tetrazole-containing rapamycin analogs with shortened half-lives HK1030771A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26
PCT/US1998/020111 WO1999015530A1 (en) 1997-09-26 1998-09-24 Tetrazole-containing rapamycin analogs with shortened half-lives

Publications (1)

Publication Number Publication Date
HK1030771A1 true HK1030771A1 (en) 2001-05-18

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100137A HK1030771A1 (en) 1997-09-26 2001-01-05 Tetrazole-containing rapamycin analogs with shortened half-lives

Country Status (28)

Country Link
EP (1) EP1015459B9 (xx)
JP (1) JP3790424B2 (xx)
KR (3) KR100700319B1 (xx)
CN (1) CN1161360C (xx)
AR (1) AR015940A1 (xx)
AT (1) ATE297398T1 (xx)
AU (1) AU745576B2 (xx)
BG (1) BG64955B1 (xx)
BR (1) BR9812305A (xx)
CA (1) CA2303934C (xx)
CO (1) CO5070656A1 (xx)
CZ (1) CZ299365B6 (xx)
DE (1) DE69830502T2 (xx)
DK (1) DK1015459T3 (xx)
ES (1) ES2244087T3 (xx)
HK (1) HK1030771A1 (xx)
HU (1) HU228368B1 (xx)
IL (2) IL134607A0 (xx)
NO (1) NO325813B1 (xx)
NZ (2) NZ514778A (xx)
PL (1) PL191212B1 (xx)
PT (1) PT1015459E (xx)
SI (1) SI1015459T1 (xx)
SK (1) SK285408B6 (xx)
TR (1) TR200000778T2 (xx)
TW (1) TW557297B (xx)
WO (1) WO1999015530A1 (xx)
ZA (1) ZA988750B (xx)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE347908T1 (de) * 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
NZ536513A (en) 2002-05-16 2007-10-26 Novartis Ag Use of EDG receptor binding agents in cancer
CN100351244C (zh) 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
BR0314013A (pt) * 2002-09-06 2005-07-12 Abbott Lab Equipamento médico contendo inibidor de hidratação
BR0314760A (pt) 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
US7417065B2 (en) 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2585840A1 (en) 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
EP1909973B1 (en) 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
ES2611307T3 (es) 2005-08-30 2017-05-08 University Of Miami Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
BRPI0714945B8 (pt) * 2006-07-25 2021-05-25 Abbott Lab composições de análogo de rapamicina e processos para preparação de formas cristalinas de análogos de rapamicinas
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
WO2008086369A1 (en) 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CN105198997B (zh) 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
EA020655B1 (ru) 2008-04-17 2014-12-30 Миселл Текнолоджиз, Инк. Стенты, имеющие биорассасывающиеся слои
CA2728514C (en) 2008-06-20 2020-08-11 Novartis Ag Paediatric compositions for treating multiple sclerosis
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
DK2676953T3 (en) 2008-12-18 2017-07-03 Novartis Ag Hemifumarate salt of 1- [4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl] -acetidine-3-carboxylic acid for use in the treatment of lymphocyte-mediated diseases
BRPI0922466A2 (pt) 2008-12-18 2018-10-23 Novartis Ag sais
CN102256942B (zh) 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
SG178125A1 (en) 2009-08-03 2012-03-29 Univ Miami Method for in vivo expansion of t regulatory cells
MX2012005023A (es) 2009-10-30 2012-06-19 Ariad Pharma Inc Metodos y composiciones para tratar cancer.
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
PE20160841A1 (es) * 2010-02-11 2016-09-10 Bristol Myers Squibb Co Macrociclos como inhibidores del factor de coagulacion (fxia)
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
KR101620661B1 (ko) 2010-04-27 2016-05-12 로슈 글리카트 아게 어푸코실화된 ＣＤ20 항체와 mTOR 억제제의 복합 요법
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
US20130172853A1 (en) 2010-07-16 2013-07-04 Micell Technologies, Inc. Drug delivery medical device
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
EP3309148A1 (en) 2011-10-14 2018-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2906551B1 (en) 2012-10-12 2018-02-28 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP2016500112A (ja) * 2012-11-30 2016-01-07 ハンジョウ ジロックス ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｚｙｌｏｘ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． ラパマイシン類似体及びその製作方法
KR20150136047A (ko) 2013-01-09 2015-12-04 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
AU2014265460B2 (en) 2013-05-15 2018-10-18 Micell Technologies, Inc. Bioabsorbable biomedical implants
BR112016010716A8 (pt) 2013-11-13 2020-04-22 Novartis Ag dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
LT3099687T (lt) 2014-01-31 2018-09-10 Bristol-Myers Squibb Company Makrociklai su heterociklinėmis p2' grupėmis kaip faktoriaus xia inhibitoriai
NO2760821T3 (xx) 2014-01-31 2018-03-10
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
PL3129470T3 (pl) 2014-04-07 2021-11-29 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
KR102594343B1 (ko) 2014-07-21 2023-10-26 노파르티스 아게 Cd33 키메라 항원 수용체를 사용한 암의 치료
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
CN107108744B (zh) 2014-08-19 2020-09-25 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
EP4234685A3 (en) 2015-04-17 2023-09-06 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
AU2016352806A1 (en) 2015-11-11 2018-05-10 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
BR112019010470A2 (pt) 2016-11-23 2019-09-10 Novartis Ag métodos de realce de resposta imune com everolimo, dactolisib ou ambos
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
JP2022510573A (ja) 2018-07-23 2022-01-27 エンクリアー セラピーズ， インク． 神経障害の治療方法
EP3952947A1 (en) 2019-04-11 2022-02-16 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
JP2023550544A (ja) 2020-11-03 2023-12-01 アールディスカバリー エルエルシー がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
CN116082362A (zh) * 2023-01-04 2023-05-09 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
EP0927182A2 (en) * 1996-09-09 1999-07-07 American Home Products Corporation Alkylated rapamycin derivatives
WO1998009972A1 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries

Also Published As

Publication number Publication date
EP1015459A1 (en) 2000-07-05
IL134607A0 (en) 2001-04-30
SK4172000A3 (en) 2000-08-14
DE69830502D1 (de) 2005-07-14
KR100700319B1 (ko) 2007-03-29
BR9812305A (pt) 2000-09-05
IL134607A (en) 2006-04-10
KR100833812B1 (ko) 2008-05-30
JP2001517671A (ja) 2001-10-09
CO5070656A1 (es) 2001-08-28
PL339455A1 (en) 2000-12-18
AR015940A1 (es) 2001-05-30
TW557297B (en) 2003-10-11
SK285408B6 (sk) 2007-01-04
BG64955B1 (bg) 2006-10-31
NZ502896A (en) 2001-12-21
HU228368B1 (en) 2013-03-28
WO1999015530A1 (en) 1999-04-01
KR20070086925A (ko) 2007-08-27
CA2303934C (en) 2010-01-26
NO20001438L (no) 2000-05-26
PT1015459E (pt) 2005-09-30
HUP0004556A2 (hu) 2001-10-28
TR200000778T2 (tr) 2000-07-21
AU745576B2 (en) 2002-03-21
KR100803639B1 (ko) 2008-02-19
ES2244087T3 (es) 2005-12-01
DK1015459T3 (da) 2005-10-10
CZ299365B6 (cs) 2008-07-02
NZ514778A (en) 2005-01-28
CA2303934A1 (en) 1999-04-01
SI1015459T1 (en) 2005-10-31
CZ20001014A3 (cs) 2000-07-12
JP3790424B2 (ja) 2006-06-28
EP1015459B1 (en) 2005-06-08
NO325813B1 (no) 2008-07-21
ZA988750B (en) 1999-04-01
KR20010024298A (ko) 2001-03-26
HUP0004556A3 (en) 2001-12-28
CN1271361A (zh) 2000-10-25
KR20060071092A (ko) 2006-06-26
BG104316A (en) 2000-12-29
AU9581998A (en) 1999-04-12
CN1161360C (zh) 2004-08-11
PL191212B1 (pl) 2006-03-31
NO20001438D0 (no) 2000-03-20
ATE297398T1 (de) 2005-06-15
EP1015459B9 (en) 2005-10-12
DE69830502T2 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
IL134607A0 (en) Tetrazole-containing rapamycin analogs with shortened half-lives
GB9720997D0 (en) Shock absorber
GB2345698B (en) Phthalocyanine analogs
DE59814003D1 (en) Thienopyrimidine
GB9809594D0 (en) Shock absorber
GB2328999B (en) Shock absorber
GB2325719B (en) Shock absorbing support
TW396962U (en) Mechanical pencil
TW389171U (en) Mechanical pencil
PL336307A1 (en) Crambescidin compounds
TW356768U (en) Double-chuck type mechanical pencil
GB9811463D0 (en) A body support
GB9719216D0 (en) Pen
GB9706700D0 (en) Absorber
TW322017U (en) Improved motocycle shock absorber
CA79779S (en) Banc
TW352699U (en) Improved structure for shock absorber
TW371922U (en) Pens
PL106250U1 (en) Derailer
TW322846U (en) Different-axis non-sharpening pencil
PL319446A1 (en) External stabiliser
GB9720357D0 (en) Bicycle stabiliser
GB9719305D0 (en) Pencil extension
GB9710441D0 (en) Pencils
GB9722718D0 (en) Lock-seal external

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180923